Omeros Co.

Omeros reported adjusted earnings of $0.02 per share and net revenue of $28.5 million for the second quarter, well above expectations. The main driver was the commercial launch of the FDA‑approved antibody Yartemlea for the treatment of TA‑TMA, giving the company a monopoly position. Omeros also generated positive operating cash flow of $4.1 million. » Más en finanzen.net

Omeros shares rose to a new 52-week high of $18.16, lifting market capitalization to around $1.31 billion. In the second quarter the company comfortably beat analysts’ expectations with adjusted earnings of $0.02 per share and revenue of $28.5 million, supported by the launch of YARTEMLEA. Data from InvestingPro point to an overbought RSI level and a possible overvaluation of the stock. » Más en de.investing.com

Omeros reported adjusted earnings of $0.02 per share and revenue of $28.5 million for Q2 2026, well above consensus estimates. Gross product revenue from YARTEMLEA was $32.2 million in the first full quarter of launch and contributed materially to positive operating cash flow of $4.1 million. Management expects higher selling and R&D expenses in Q3 but provided no revenue guidance; the stock rose about 20% in after-hours trading. » Más en de.investing.com

After an oral explanation meeting the CHMP adopted a negative opinion on Omeros' narsoplimab marketing application. Omeros plans to request reconsideration and an assessment by an EMA Ad Hoc Expert Panel. H.C. Wainwright cut its price target from $40 to $33 but kept a Buy rating, citing the U.S. launch as the key value driver. » Más en finance.yahoo.com

Omeros has entered privately negotiated agreements to repurchase its 9.50% convertible notes due 2029 with a principal amount of up to about $16 million; the total purchase price including interest is expected to be up to about $34 million and will be partly determined by the share price during an upcoming averaging period. The repurchases are expected to settle between July 6 and 16; if fully repurchased, about $54.8 million in principal would remain outstanding. At the same time, Omeros significantly missed expectations for revenue and EPS in Q1 2026, while H.C. Wainwright remains at a buy rating with a $40 price target and highlights key data releases due mid‑2026. » Más en de.investing.com